Results from a Cross-Sectional Observational Study Examining Irritable Bowel Syndrome Patients Six Months After Finishing Their Participation in the ViIBS Trial

Overview

Journal Nutrients

Date 2024 Nov 27

PMID 39599697

Authors

Henning Sommermeyer

Krzysztof Chmielowiec

Malgorzata Bernatek

Pawel Olszewski

Jaroslaw Kopczynski

Jacek Piatek

Affiliations

Soon will be listed here.

Abstract

Background/objectives: A recent clinical (ViIBS) trial investigating the effects of a balanced multi-strain synbiotic in irritable bowel syndrome (IBS) patients showed that twelve weeks of treatment resulted in significant improvements across all major IBS symptoms. The current observational study pursued three aims: investigate patients' attitude towards the intake of pro- or synbiotics during the six months after finishing their trial participation, determine the severity of IBS symptoms, and assess IBS diagnosis scores.

Methods: During a single six-month follow-up examination, patients were asked about the intake of probiotics or synbiotics. For the study, former placebo-group patients who abstained from taking probiotics were compared with synbiotic-group patients who continued taking the tested synbiotic. IBS symptom severity was assessed with the IBS-Severity of Symptoms Scale and the IBS diagnosis score with the IBS questionnaire of the World Gastroenterology Organisation.

Results: The control group comprised 17 patients (out of 70 from the placebo group participating in the follow-up) and the treatment group 75 (out of 91 examined). IBS symptom severity was significantly lower in the treatment group (23.5 ± 33.1) than in the placebo group (232.6 ± 35.1). IBS diagnosis scores were 5.9 ± 2.5 and 21.2 ± 2.0 in the treatment and control group, respectively.

Conclusions: Measurement values for the treatment group indicate the absence of IBS. The results indicate that the prolonged administration of the balanced multi-strain synbiotic can potentially reduce IBS symptom severity and IBS diagnosis scores to levels indicating the absence of IBS, an observation to be followed up in a controlled clinical trial.

References

Black C, Ford A . Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020; 17(8):473-486. DOI: 10.1038/s41575-020-0286-8. View

Sommermeyer H, Chmielowiec K, Bernatek M, Olszewski P, Kopczynski J, Piatek J . Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients-A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2024; 16(10). PMC: 11123967. DOI: 10.3390/nu16101503. View

van der Geest A, Schukking I, Brummer R, van de Burgwal L, Larsen O . Comparing probiotic and drug interventions in irritable bowel syndrome: a meta-analysis of randomised controlled trials. Benef Microbes. 2022; 13(3):183-194. DOI: 10.3920/BM2021.0123. View

Ceccherini C, Daniotti S, Bearzi C, Re I . Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis. Nutrients. 2022; 14(13). PMC: 9268703. DOI: 10.3390/nu14132689. View

Lovell R, Ford A . Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7):712-721.e4. DOI: 10.1016/j.cgh.2012.02.029. View

Ford A, Sperber A, Corsetti M, Camilleri M . Irritable bowel syndrome. Lancet. 2020; 396(10263):1675-1688. DOI: 10.1016/S0140-6736(20)31548-8. View

Lu C, Chang F . Placebo effect in patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2011; 26 Suppl 3:116-8. DOI: 10.1111/j.1440-1746.2011.06651.x. View

Sommermeyer H, Piatek J . Synbiotics as Treatment for Irritable Bowel Syndrome: A Review. Microorganisms. 2024; 12(7). PMC: 11278745. DOI: 10.3390/microorganisms12071493. View

Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E . Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci. 2003; 48(7):1317-23. DOI: 10.1023/a:1024159226274. View

10.

Kerckhoffs A, Samsom M, van der Rest M, de Vogel J, Knol J, Ben-Amor K . Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009; 15(23):2887-92. PMC: 2699007. DOI: 10.3748/wjg.15.2887. View

11.

Francis C, Morris J, Whorwell P . The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997; 11(2):395-402. DOI: 10.1046/j.1365-2036.1997.142318000.x. View

12.

Wang X, Cheng Z . Cross-Sectional Studies: Strengths, Weaknesses, and Recommendations. Chest. 2020; 158(1S):S65-S71. DOI: 10.1016/j.chest.2020.03.012. View

13.

Piatek J, Gibas-Dorna M, Olejnik A, Krauss H, Wierzbicki K, Zukiewicz-Sobczak W . The viability and intestinal epithelial cell adhesion of probiotic strain combination--in vitro study. Ann Agric Environ Med. 2012; 19(1):99-102. View

14.

Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J . Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology. 2016; 152(1):111-123.e8. DOI: 10.1053/j.gastro.2016.09.049. View

15.

Passos M, Lembo A, Conboy L, Kaptchuk T, Kelly J, Quilty M . Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol. 2009; 104(4):912-9. PMC: 2707022. DOI: 10.1038/ajg.2009.13. View

16.

Hill C, Guarner F, Reid G, Gibson G, Merenstein D, Pot B . Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11(8):506-14. DOI: 10.1038/nrgastro.2014.66. View

17.

Tornkvist N, Aziz I, Whitehead W, Sperber A, Palsson O, Pall Hreinsson J . Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European Gastroenterol J. 2021; 9(10):1178-1188. PMC: 8672084. DOI: 10.1002/ueg2.12153. View

18.

Kolida S, Gibson G . Synbiotics in health and disease. Annu Rev Food Sci Technol. 2011; 2:373-93. DOI: 10.1146/annurev-food-022510-133739. View

19.

Kolamunnage-Dona R, Powell C, Williamson P . Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study. Trials. 2016; 17(1):222. PMC: 4849065. DOI: 10.1186/s13063-016-1342-0. View

20.

Zhang W, Shi L, Zhou M, Wu J, Shi H . Efficacy of probiotics, prebiotics and synbiotics in irritable bowel syndrome: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. J Med Microbiol. 2023; 72(9). DOI: 10.1099/jmm.0.001758. View